Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.

Also called NCT01890421

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 426 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01890421
  • EudraCT 2012-002563-10
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, France, Germany, New Zealand, South Korea, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01890421. Allocation not applicable; no masking; primary purpose diagnostic. Start 2013-07-19 (actual); primary completion 2015-04-10 (actual). Results posted on 2018-05-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Acronym
GadaCAD 1
Intervention (Drug)
Gadobutrol (Gadovist, Gadavist, BAY86-4875)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01890421
Content hash
dc23e51b289123c6dd2387ee614f77497a161691a905f55ec2b7a6efe09909db